医用MRI核心部件

Search documents
健信超导销量下降拟募8.65亿扩产 IPO前分红6000万实控人落袋过半
Chang Jiang Shang Bao· 2025-05-19 00:39
Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. (hereinafter referred to as "Jianxin Superconducting") is pushing for an IPO on the Sci-Tech Innovation Board, with a global market share of approximately 4.2% in 2024, ranking fifth globally in the medical MRI core component supply sector [1][2]. Group 1: Company Performance - Jianxin Superconducting's revenue from 2022 to 2024 was 359 million yuan, 451 million yuan, and 425 million yuan respectively, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan [2][3]. - The company's gross profit margins for the same period were 19.56%, 22.84%, and 24.94%, significantly lower than the industry average of 46.27%, 45.59%, and 45.17% [3]. Group 2: Research and Development - Jianxin Superconducting's R&D expenses from 2022 to 2024 were 20.33 million yuan, 24.42 million yuan, and 27.65 million yuan, with R&D expense ratios of 5.66%, 5.42%, and 6.50% [3]. - The cumulative R&D investment over the last three years was 72.40 million yuan, accounting for 5.86% of total revenue [3]. Group 3: Customer Concentration - The company has a high customer concentration, with sales to the top five customers accounting for 73.75%, 76.68%, and 79.62% of total revenue in the respective years [4]. - The largest customer, Fujifilm Group, represented 34.2%, 44.2%, and 42.71% of sales revenue during the same period [4]. Group 4: Future Plans and Funding - Jianxin Superconducting plans to raise up to 865 million yuan through the IPO, primarily for capacity expansion and working capital [1][5]. - The company has consistently paid dividends, totaling approximately 60 million yuan from 2022 to 2024, with over half of this amount benefiting the controlling family [6].